<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-3466</journal-id>
<journal-title><![CDATA[Revista Cubana de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Salud Pública]]></abbrev-journal-title>
<issn>0864-3466</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-34662018000400112</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo del tratamiento farmacológico de las reacciones adversas graves por medicamentos en Cuba (2003-2013)]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost of Pharmacological Treatment for Serious Adverse Drug Reactions in Cuba (2003-2013)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez López]]></surname>
<given-names><![CDATA[Giset]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gálvez González]]></surname>
<given-names><![CDATA[Ana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Fariñas]]></surname>
<given-names><![CDATA[Anai]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED)  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Escuela Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>44</volume>
<numero>4</numero>
<fpage>112</fpage>
<lpage>124</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-34662018000400112&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-34662018000400112&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-34662018000400112&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Los problemas de seguridad y costo de las reacciones adversas medicamentosas (RAM) graves tienen un peso considerable en los sistemas de salud, pero la evidencia demostrada en los estudios publicados en Cuba, es aún escasa.  Objetivo:  Determinar costos asociados al tratamiento farmacológico de las reacciones adversas graves en el país.  Método:  Se realizó una evaluación parcial de tipo descripción de costos desde la perspectiva del Sistema Nacional de Salud en el periodo 2003-2013. Se utilizó una técnica de microcosteo, se calcularon los costos unitarios y totales para un horizonte temporal de 24 horas de ocurrida la reacción adversa grave y estos se expresaron en pesos cubanos.  Resultados:  Del total de RAM graves, en 13 293 hubo descripción del tratamiento farmacológico inmediato (17,9 %). Este representó un costo total de $ 62 228,05. El costo medio fue de $ 4,69. Los mayores porcentajes de RAM graves se ubicaron en los rangos entre $ 1,00 y 3,00 (24,3 %). Se observó que las RAM de hipersensibilidad representaron el 34,2 % del costo total con $ 21 283,41 CUP. Aquellas de intensidad moderada representaron el 81,7 % de los costos. Prácticamente en todos los casos costó más tratar las RAM graves que el costo del tratamiento farmacológico que la originó.  Conclusiones: Los resultados muestran que las RAM graves verifican un problema y generan un costo para el sistema nacional de salud, por lo que se requieren medidas encaminadas a su detección y prevención para mejorar la seguridad del paciente y reducir los costos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: The safety and cost problems of serious adverse drug reactions (ADRs) have a considerable weight in health systems, but the evidence shown in the studies published in Cuba is still scarce.  Objective: To determine costs associated with the pharmacological treatment of serious adverse reactions in the country.  Method: A partial evaluation of cost description was carried out from the perspective of the National Health System in the 2003-2013 period. A micro-costing method was used. Unit and total costs were calculated for a time horizon of 24 hours after the serious adverse reaction occurred and these were expressed in Cuban pesos.  Results:  13 293 of the total of serious AMR had a description of the immediate pharmacological treatment (17.9 %). This represented a total cost of $ 62,228.05. The average cost was $ 4.69. The highest percentages of serious RAM were in the ranges between $ 1.00 and $ 3.00 CUP (24.3 %). Hypersensitivity ADRs represented 34.2 % of the total cost with $ 21,283.41 CUP. Those of moderate intensity represented 81.7 %. In practically all cases, it cost more to treat serious ADRs than the cost of the pharmacological treatment that originated it.  Conclusions:  The results showed that serious ADRs prove to be a problem and generate costs for the national health system, which is why measures aimed at its detection and prevention are required to improve patient safety hence reduce costs.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[farmacovigilancia]]></kwd>
<kwd lng="es"><![CDATA[reacción adversa a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[reacción adversa grave]]></kwd>
<kwd lng="es"><![CDATA[costos]]></kwd>
<kwd lng="es"><![CDATA[evaluación económica]]></kwd>
<kwd lng="en"><![CDATA[pharmacovigilance]]></kwd>
<kwd lng="en"><![CDATA[adverse reaction to medications]]></kwd>
<kwd lng="en"><![CDATA[serious adverse reaction]]></kwd>
<kwd lng="en"><![CDATA[costs]]></kwd>
<kwd lng="en"><![CDATA[economic evaluation.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salas Rojas]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Morales]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Meléndez López]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Pastrana]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a medicamentos relacionadas con ingresos y estancias hospitalarias revisión sistemática de 2000-2011]]></article-title>
<source><![CDATA[Rev Mex Cienc Farm]]></source>
<year>2012</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>19-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lecointre]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Noblet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mabille]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuency and cost of serious adverse reactions in a department of general medicine]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1998</year>
<volume>45</volume>
<page-range>301-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazarou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of adverse drug reactions in hospitalised patients a meta-analysis of prospective studies]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1998</year>
<volume>279</volume>
<page-range>1200-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urmimala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maselli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse Drug Events in U S. Adult ambulatory medical care]]></article-title>
<source><![CDATA[Health Services Research]]></source>
<year>2011</year>
<volume>46</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1517-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Ann</collab>
<source><![CDATA[Guidance for industry-good pharmacovigilance practices and pharmacoepidemiologic assessment US food and drug administration]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Elixhauser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Medication-Related Adverse Outcomes in US hospitals and emergency departments 2008. Statistical Brief #109HCUP]]></source>
<year>2011</year>
<publisher-name><![CDATA[Agency for Healthcare Research and Quality, Rockville, MD]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vries]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Ramrathan]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Smorenburg]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Gouma]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boermeester]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence and nature of in-hospital adverse events a systematic review]]></article-title>
<source><![CDATA[AM Qual Saf Health Care]]></source>
<year>2008</year>
<volume>17</volume>
<page-range>216-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Castiella]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sanjuán]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Naya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad del CMBD para la detección de acontecimientos adversos por medicamentos]]></article-title>
<source><![CDATA[An Med Interna]]></source>
<year>2007</year>
<volume>24</volume>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pouyanne]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Admission to hospital caused by adverse drug reactions cross sectional incidence study]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[f]]></surname>
<given-names><![CDATA[Haramburu]]></given-names>
</name>
<name>
<surname><![CDATA[l]]></surname>
<given-names><![CDATA[Imbs]]></given-names>
</name>
<name>
<surname><![CDATA[Beagud]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>320</volume>
<page-range>1036</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salas Rojas]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Morales]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Meléndez López]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Pastrana]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a medicamentos relacionadas con ingresos y estancias hospitalarias revisión sistemática de 2000-2011]]></article-title>
<source><![CDATA[Rev Mex Cienc Farm]]></source>
<year>2012</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>19-35</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallano Ferraz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Agustí Escasany]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrós Xolvi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión sistemática de los estudios de evaluación del costo de las reacciones adversas a medicamentos]]></article-title>
<collab>Arnau de Bolós JM</collab>
<source><![CDATA[Gac Sanit]]></source>
<year>2012</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>277-83</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Renee Stark]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jürgen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Reiner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health care use and costs of adverse drug events emerging from outpatient treatment in Germany A modelling approach. Starketal]]></article-title>
<source><![CDATA[BMC Health Services Research]]></source>
<year>2011</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shuster]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ISMP adverse drug reactions]]></article-title>
<source><![CDATA[Hosp Pharm]]></source>
<year>2009</year>
<volume>44</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>658-61</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Cuadro básico de medicamentos año 2014]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Departamento de Farmacoepidemiología. Dirección de Medicamentos y Tecnologías Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Centro para el desarrollo de la Farmacoepidemiología. Unidad Coordinadora Nacional de Farmacovigilancia</collab>
<source><![CDATA[Informe Anual]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[OI]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Triolet]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a medicamentos en una unidad de terapia intensiva]]></article-title>
<source><![CDATA[Electron J Biomed]]></source>
<year>2008</year>
<volume>2</volume>
<page-range>10-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[GO]]></given-names>
</name>
<name>
<surname><![CDATA[Casamayor]]></surname>
<given-names><![CDATA[LZ]]></given-names>
</name>
<name>
<surname><![CDATA[Nápoles]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Calzadilla]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Sotolongo]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sospechas de reacciones adversas medicamentos en servicios de terapia]]></article-title>
<source><![CDATA[Rev Cub Med Mil]]></source>
<year>2008</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rego]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leyva]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pesquisaje activo de sospechas de reacciones adversas a medicamentos en el Hospital "Dr. Salvador Allende". Primer semestre 2006]]></article-title>
<source><![CDATA[Rev Cub Farm]]></source>
<year>2007</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez López]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lara Bastanzuri]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bayarre Vea]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rego Hernández]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[García Arzola]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costo de los efectos adversos que causan ingreso en hospitales seleccionados de Ciudad de La Habana 2006]]></article-title>
<source><![CDATA[Boletín medicamentos]]></source>
<year>2009</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Proyecciones de la salud pública en Cuba hasta el 2015]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Ciudad de la Habana ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Transformaciones necesarias en el Sistema de Salud Pública]]></source>
<year>2010</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Sculpher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[O´Brien]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<source><![CDATA[Methods for the economic evaluation of health care programmes]]></source>
<year>2005</year>
<edition>3</edition>
<publisher-loc><![CDATA[US ]]></publisher-loc>
<publisher-name><![CDATA[Oxford University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>Dirección de Medicamentos y tecnologías Médicas</collab>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ecimed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gálvez González]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía metodológica para la evaluación económica en salud: Cuba, 2003]]></article-title>
<source><![CDATA[Rev Cubana Salud Pública]]></source>
<year>2004</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaro]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Ética médica y bioética]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Ciudad de la Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS)</collab>
<source><![CDATA[Pautas para la ética en la investigación y práctica epidemiológica]]></source>
<year>1991</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las reacciones adversas a medicamentos una aproximación desde el punto de vista económico]]></article-title>
<source><![CDATA[Biomédica,]]></source>
<year>2003</year>
<volume>23</volume>
<page-range>401-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puche Cañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a medicamentos en pacientes que acudieron a un hospital general un metaanálisis de resultados]]></article-title>
<collab>Luna del Castillo JD</collab>
<source><![CDATA[An. Med. Interna]]></source>
<year>2007</year>
<volume>24</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>574-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinzón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costos directos e impacto sobre la morbimortalidad hospitalaria de eventos adversos prevenibles a medicamentos en una institución de tercer nivel de Bogotá]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2011</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>307-15</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gyllensten]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rehnberg]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jönsson]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2013</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allué]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarello]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Castells]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sarsanedas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto económico de los eventos adversos en los hospitales españoles a partir del Conjunto Mínimo Básico de Datos]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2014</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-54</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tribiño]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costos directos y aspectos clínicos de las reacciones adversas a medicamentos en pacientes hospitalizados en el servicio de Medicina Interna de una institución de tercer nivel de Bogotá]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2006</year>
<volume>26</volume>
<numero>001</numero>
<issue>001</issue>
<page-range>31-41</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Rojas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Tamayo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez López]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Casas Cruz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización y costo de reacciones adversas medicamentosas. Hospital Lucia Iñiguez. 2010]]></article-title>
<source><![CDATA[Rev Cub Farm]]></source>
<year>2012</year>
<volume>46</volume>
<numero>^ssupl. 1</numero>
<issue>^ssupl. 1</issue>
<supplement>supl. 1</supplement>
<page-range>1-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
